Business
Endonovo Therapeutics Announces Immunotronic and Cytotronic Platforms
Endonovo Therapeutics Announces Immunotronic and Cytotronic Platforms.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n \n \n Endonovo Therapeutics Announces Immunotronic and Cytotronic Platforms\n \n \nEndonovo Therapeutics Announces Immunotronic and Cytotronic Platforms\n\nBioelectronics-Based Platforms Seek to Address Inflammatory Conditions in Vital Organs, Including Acute Organ Failure and Cell/Tissue Engineering\n\n \n LOS ANGELES, CA--(Marketwired - Oct 6, 2015) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\"), an innovative biotechnology company developing bioelectronic products and therapies for regenerative medicine, announced two bioelectronic-based platforms for regenerative medicine. \n Immunotronics™, a non-invasive and non-implantable immuno-regulatory device designed to treat inflammatory conditions in vital organs, including acute organ failure; \n and Cytotronics™, a proprietary bioelectronic-based method of expanding and manipulating cells for the creation of cell therapies and tissue engineering.\n Bioelectronics/Electroceuticals have raised significant attention due to their potential ability in treating a wide array of conditions including heart failure, asthma, diabetes, incontinence and arthritis while reducing unwanted side effects associated with the use of drugs.\n Last year the National Institutes of Health (NIH) announced a $248-million effort to map the body's electrical wiring and develop electroceuticals. It will announce this upcoming autumn the first funding from the Stimulating Peripheral Activity to Relieve Conditions (SPARC) program. Additionally, DARPA, the Pentagon's blue-skies research arm, will announce the recipients of its $80 million ElectRx initiative, a program that is part of the defense agency's year-old biotech unit designed to advance discoveries that may help wounded warriors and others. GlaxoSmithKline, is leading the private sector's funding of electroceuticals by investing up to $50 million in bioelectronic startups and $5 million more in basic research to map the body's electrical wiring and how it may affect chronic diseases. \n Endonovo is concentrating its efforts on inflammatory conditions in vital organs and previously announced it's in the pre-clinical phase of assessing its proprietary Immunotronic technology in the treatment of chronic and acute inflammatory conditions in the liver, including fulminant liver failure. \n Endonovo Chief Medica...